相关实验视频

Updated: Jul 26, 2025

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

首批英国患者队列接受了用于原发性癌的立体性废除性放射治疗

Anjali Zarkar¹, Dan Henderson¹, Antony Carver¹

¹University Hospitals Birmingham NHS Foundation Trust Birmingham UK.

|June 19, 2023

概括

对于癌而言,立体性废除性辐射疗法 (SABR) 是安全有效的. 这项研究表明,SABR为原发性细胞癌患者提供了良好的局部控制和生存率.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
腎臟病學 (nephrology) 是一種醫學.

背景情况:

立体除性放射治疗 (SABR) 是一种新兴的非侵入性治疗原发性细胞癌 (RCC) 的方法.
以前的研究表明可行性和耐受性,但来自英国中心的数据有限.

研究的目的:

介绍英国第一个单一机构队列的初级RCC患者,他们接受了基于协议的SABR治疗.
报告潜在的毒性和结果数据.
为英国癌症中心更广泛地实施SABR提供一个协议.

主要方法:

19名初级RCC患者在线加速器或CyberKnife上接受了SABR (42 Gy分为3个小部分或26 Gy分为1个小部分).
使用CTCAE V4.0.0.进行毒性评估.
包括eGFR和瘤反应 (CT-TAP) 在内的结果被监测了长达24个月.

主要成果:

患者的中位年龄为76岁,中位瘤大小为4.5厘米.
SABR耐受性很好,没有急性严重的副作用.
12个月后平均eGFR下降为8.7毫升/分钟.
12个月后的局部控制率为94.4%.
在12个月的总生存率为78.3%.

结论:

SABR是初级RCC的安全和可行的治疗选择,特别是对于医疗不适合的患者.
在英国的癌症中心,可以使用标准的线性加速器和CyberKnife平台进行治疗.
该研究提供了一项协议,以促进SABR在RCC的更广泛采用.

关键词:

SABR SABR是一款 SABR 系列的车型.对于初级RCC的SABR,这是一个SABR.在SBRT和SBRT之间.对于初级RCC,SBRT是主要的RCC.一级脏SABR SABR 是一个初级脏.刻板印象的废除性放射疗法.立体电磁辐射疗法立体电磁辐射疗法

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

相关概念视频

Kidney Transplant I: Introduction

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...